Literature DB >> 27211996

Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification.

Lisa A Uebelacker1, Genie Bailey2, Debra Herman3, Bradley Anderson4, Michael Stein3.   

Abstract

Subsequent to initial opioid detoxification, people with opioid use disorder are typically advised to engage in follow-up treatment to prevent relapse. Medication-assisted treatments (MATs) - i.e., the opioid agonist methadone (MMT) or partial agonist/antagonist, buprenorphine/naltrexone (BUP) -- are the maintenance treatment options with the best research support for positive outcomes. A third MAT, injectable extended-release naltrexone (XR-NTX), was approved by the FDA for opioid dependence in 2010 and shows promise. However, relatively few eligible patients choose to initiate one of these MATs following initial detoxification treatment. Consistent with the health belief model, we hypothesized that beliefs about 1) efficacy of each MAT; 2) safety of each MAT; and 3) perceived consistency with being drug-free would predict stated patient preferences for a particular MAT or for no MAT. We also hypothesized that perceived structural barriers (e.g., time, transportation) would decrease the likelihood of stating a preference for a given MAT. To assess these hypotheses, we surveyed 372 people undergoing inpatient opioid detoxification treatment. Results supported hypotheses for all 3 sets of patient beliefs, with the patient group stating that they preferred a particular MAT having significantly more positive beliefs about that MAT relative to other groups (p<.001). The group that preferred "no MAT" had the most negative beliefs about all MATs. Perceived structural barriers were not related to stated preferences, except that people who preferred BUP were more likely to endorse barriers to MMT than any of the other 3 groups. Notably, a relatively high proportion (32%) of participants were most interested in XR-NTX despite a lack of prior experience with this medication. These results suggest that efforts to increase MAT enrollment following detoxification might benefit from including patient beliefs as one set of factors to assess and target for change.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Methadone; Naltrexone; Opioids; Preferences

Mesh:

Substances:

Year:  2016        PMID: 27211996      PMCID: PMC4892369          DOI: 10.1016/j.jsat.2016.02.009

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  29 in total

1.  Detoxification as a gateway to long-term treatment: assessing two interventions.

Authors:  Mari Millery; Bhadra Paula Kleinman; Nayak L Polissar; Robert B Millman; Michael Scimeca
Journal:  J Subst Abuse Treat       Date:  2002-10

2.  The art and science of patient storytelling-harnessing narrative communication for behavioral interventions: the ACCE project.

Authors:  Thomas K Houston; Andrea Cherrington; Heather L Coley; Kimberly M Robinson; John A Trobaugh; Jessica H Williams; Pamela H Foster; Daniel E Ford; Ben S Gerber; Richard M Shewchuk; Jeroan J Allison
Journal:  J Health Commun       Date:  2011-05-24

3.  Social learning theory and the Health Belief Model.

Authors:  I M Rosenstock; V J Strecher; M H Becker
Journal:  Health Educ Q       Date:  1988

4.  Client and counselor attitudes toward the use of medications for treatment of opioid dependence.

Authors:  Traci Rieckmann; Marilyn Daley; Bret E Fuller; Cindy P Thomas; Dennis McCarty
Journal:  J Subst Abuse Treat       Date:  2006-12-08

Review 5.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Authors:  M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

6.  "Should I stay or should I go?" Coming off methadone and buprenorphine treatment.

Authors:  Adam R Winstock; Nicholas Lintzeris; Toby Lea
Journal:  Int J Drug Policy       Date:  2010-10-16

7.  The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.

Authors:  Bradley D Stein; Adam J Gordon; Mark Sorbero; Andrew W Dick; James Schuster; Carrie Farmer
Journal:  Drug Alcohol Depend       Date:  2011-11-16       Impact factor: 4.492

8.  Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

Authors:  Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman
Journal:  Lancet       Date:  2011-04-30       Impact factor: 79.321

9.  Long term substitution treatment (maintenance treatment) of opioid dependent persons.

Authors:  Martin Busch; Sabine Haas; Marion Weigl; Charlotte Wirl
Journal:  GMS Health Technol Assess       Date:  2007-03-27

10.  Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds.

Authors:  Paul J Whelan; Kimberly Remski
Journal:  J Neurosci Rural Pract       Date:  2012-01
View more
  40 in total

1.  Outpatient care for opioid use disorder among the commercially insured: Use of medication and psychosocial treatment.

Authors:  Alisa B Busch; Shelly F Greenfield; Sharon Reif; Sharon-Lise T Normand; Haiden A Huskamp
Journal:  J Subst Abuse Treat       Date:  2020-05-22

2.  Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.

Authors:  Babak Tofighi; Arthur Robin Williams; Chemi Chemi; Selena Suhail-Sindhu; Vicky Dickson; Joshua D Lee
Journal:  Subst Use Misuse       Date:  2019-08-20       Impact factor: 2.164

3.  Attitudes toward opioid use disorder medications: Results from a U.S. national study of individuals who resolved a substance use problem.

Authors:  Brandon G Bergman; Robert D Ashford; John F Kelly
Journal:  Exp Clin Psychopharmacol       Date:  2019-09-26       Impact factor: 3.157

4.  Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine.

Authors:  Ruthanne Marcus; Iuliia Makarenko; Alyona Mazhnaya; Alexei Zelenev; Maxim Polonsky; Lynn Madden; Sergii Filippovych; Sergii Dvoriak; Sandra A Springer; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2017-08-05       Impact factor: 4.492

5.  Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial.

Authors:  Evgeny Krupitsky; Elena Blokhina; Edwin Zvartau; Elena Verbitskaya; Dmitri Lioznov; Tatiana Yaroslavtseva; Vladimir Palatkin; Marina Vetrova; Natalia Bushara; Andrei Burakov; Dmitri Masalov; Olga Mamontova; Daniel Langleben; Sabrina Poole; Robert Gross; George Woody
Journal:  Lancet HIV       Date:  2019-03-14       Impact factor: 12.767

6.  Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.

Authors:  Brantley P Jarvis; August F Holtyn; Meredith S Berry; Shrinidhi Subramaniam; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  J Subst Abuse Treat       Date:  2017-04-20

7.  Heroin refusal self-efficacy and preference for medication-assisted treatment after inpatient detoxification.

Authors:  Shannon R Kenney; Genie L Bailey; Bradley J Anderson; Michael D Stein
Journal:  Addict Behav       Date:  2017-05-09       Impact factor: 3.913

8.  Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support.

Authors:  Dharushana Muthulingam; Joshua Bia; Lynn M Madden; Scott O Farnum; Declan T Barry; Frederick L Altice
Journal:  J Subst Abuse Treat       Date:  2019-01-26

9.  Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida.

Authors:  Amanda Sharp; Melissa Carlson; Veronica Howell; Kathleen Moore; Zev Schuman-Olivier
Journal:  J Subst Abuse Treat       Date:  2020-12-11

10.  Brief video intervention to improve attitudes throughout medications for opioid use disorder in a correctional setting.

Authors:  Jeffrey A Lam; Hye In Sarah Lee; Ashley Q Truong; Alexandria Macmadu; Jennifer G Clarke; Josiah Rich; Brad Brockmann
Journal:  J Subst Abuse Treat       Date:  2019-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.